IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

Mavacamten: A Breakthrough Drug for Hypertrophic Cardiomyopathy

Kalpesh Chotu Prajapati, Walunj Kajal Bhaskar, Chanchal Goraksha Varhadi, Satyajeet Dadabhau Walunj, Omkar Santosh Bhujbhal
Department of Pharmaceutical Analysis
Samarth Institute of Pharmacy, Belhe, Maharashtra, India
drxkalpesh24@gmail.com

Abstract: *Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder marked by the abnormal thickening of the heart muscle, leading to impaired cardiac function and increased risk of life-threatening complications. Mavacamten, a groundbreaking medication, has emerged as a promising therapeutic option for managing HCM. This abstract summarizes the key aspects of Mavacamten*
Mechanism of Action: Mavacamten is a myosin inhibitor that targets the fundamental mechanical dysfunction underlying HCM. By reducing the hypercontractility of cardiac muscle fibers, Mavacamten alleviates the obstruction of blood flow from the left ventricle and improves diastolic function.
Clinical Efficacy: Clinical trials have demonstrated the efficacy of Mavacamten in reducing symptoms and improving exercise capacity in individuals with HCM. It has shown the ability to mitigate left ventricular outflow tract obstruction, thereby enhancing the quality of life for affected patients.
Safety Profile: Mavacamten has exhibited a favorable safety profile, with side effects generally being mild and manageable. Adverse events primarily include musculoskeletal issues, such as muscle spasms and pain, but severe complications are infrequent.
Future Implications: Mavacamten represents a significant advancement in the treatment of HCM. Its approval and adoption in clinical practice offer a targeted approach to manage the disease's underlying pathophysiology, potentially reducing the need for invasive procedures or cardiac surgery..

Keywords: Mavacamten, Hypertrophic Cardiomyopathy, Myosin Inhibitor, Drug Mechanism, Clinical Efficacy, Safety Profile, Treatment Review

I. INTRODUCTION



Hypertrophic Cardiomyopathy (HCM) is a genetic heart disorder characterized by the abnormal thickening of the heart muscle, often leading to debilitating symptoms and life-threatening complications. Over the years, the management of HCM has undergone significant advancements, and one of the most noteworthy developments is the emergence of Mavacamten as a promising therapeutic agent. This review aims to comprehensively evaluate Mavacamten, shedding light on its mechanism of action, clinical efficacy, safety profile, and implications for the treatment of HCM.

SIGNIFICANCE:
HCM is a relatively common genetic heart condition, impacting individuals across all age groups. Its manifestations range from mild symptoms, such as shortness of breath and chest pain, to severe, including heart failure and sudden

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

cardiac death. This condition poses a substantial burden on affected individuals and their families. Historically, treatment options have been limited, often necessitating invasive surgical interventions or relying on traditional pharmacological agents with mixed outcomes. Mavacamten's arrival on the scene signifies a significant advancement in the field of cardiology, offering a targeted and innovative approach to managing HCM. It addresses the fundamental mechanical dysfunction of the condition by inhibiting myosin, a key protein involved in muscle contraction. This review article seeks to highlight the clinical relevance and significance of Mavacamten in the treatment of HCM, providing a comprehensive assessment of its potential impact on patients' lives.

OBJECTIVES:

The objectives of this review article are as follows:

- To elucidate the mechanism of action of Mavacamten and its role in alleviating the key mechanical abnormalities underlying HCM.
- To provide a critical analysis of the clinical efficacy of Mavacamten, as demonstrated in clinical trials and real-world settings, with a focus on its impact on symptoms and exercise capacity in individuals with HCM.
- To assess the safety profile of Mavacamten, including common and rare side effects, in order to provide a comprehensive understanding of its tolerability and potential risks.
- To compare Mavacamten with existing treatment options for HCM, highlighting its advantages and limitations in managing this complex condition.
- To explore the future perspectives and ongoing research related to Mavacamten, with a particular emphasis on potential improvements in dosing regimens, combination therapies, and the evolving landscape of HCM management.

II. CLINICAL EFFICACY:

- Symptom Reduction: Mavacamten has demonstrated its efficacy in reducing the symptoms associated with HCM. Clinical trials have shown significant improvements in symptoms such as dyspnea (shortness of breath), chest pain, and exercise intolerance in patients with obstructive and non-obstructive HCM.
- Exercise Capacity: Mavacamten has been shown to enhance exercise capacity in individuals with HCM. Patients treated with Mavacamten often experience improved exercise tolerance, enabling them to engage in physical activities with less discomfort and fatigue.
- Hemodynamic Improvements: Mavacamten is effective in reducing the obstruction of blood flow from the left ventricle (left ventricular outflow tract obstruction, LVOTO), a common problem in HCM. By inhibiting myosin and reducing excessive cardiac muscle contraction, Mavacamten alleviates LVOTO, leading to improved cardiac hemodynamics.
- Reduction in Cardiac Biomarkers: Mavacamten has shown promise in reducing cardiac biomarkers associated with HCM, such as brain natriuretic peptide (BNP). Lower levels of these biomarkers often correspond to improved cardiac function and reduced strain on the heart.
- Dosage Flexibility: Clinical studies have explored different dosing regimens for Mavacamten, allowing for flexibility in tailoring treatment to individual patient needs. This adaptability is advantageous for optimizing efficacy while minimizing side effects.
- Long-Term Benefits: Some studies have suggested that the positive effects of Mavacamten persist over the long term, indicating its potential as a sustainable and effective treatment option for HCM patients.

SAFETY PROFILE:

- Generally Well-Tolerated: Mavacamten has demonstrated a generally favorable safety profile in clinical trials. Most patients tolerate the drug well, and it has been associated with a relatively low incidence of severe adverse events.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

- Musculoskeletal Symptoms: One of the most commonly reported side effects is musculoskeletal symptoms, such as muscle spasms and pain. These symptoms are typically mild to moderate in severity and often resolve with continued treatment or dose adjustments.
- Gastrointestinal Disturbances: Some patients have reported mild gastrointestinal symptoms, including nausea, diarrhea, and abdominal discomfort. These effects are generally manageable and tend to subside over time.
- Cardiovascular Effects: Mavacamten can affect the cardiovascular system, potentially leading to reductions in blood pressure and heart rate. This is a consideration for healthcare providers when prescribing the drug, particularly in patients with pre-existing low blood pressure or bradycardia.
- Dose-Dependent Effects: The incidence and severity of side effects appear to be dose-dependent, which means that some patients may experience fewer side effects at lower doses.
- Rare Side Effects: Although rare, there have been reports of more serious side effects, including ventricular arrhythmias and cardiac conduction disturbances. These adverse events are infrequent and require close monitoring.
- Drug Interactions: Mavacamten may interact with other medications, particularly those that affect heart rate or blood pressure. Healthcare providers must carefully assess potential drug interactions when prescribing Mavacamten.
- Patient Monitoring: Patients taking Mavacamten typically require regular monitoring, including cardiac assessments, to ensure their safety and to detect and manage any adverse effects promptly.
- Individual Variability: Patient responses to Mavacamten can vary, and healthcare providers may need to make individualized adjustments in dosing and treatment plans to optimize safety and efficacy.

III. COMPARISON WITH ALTERNATIVE TREATMENTS

1. Mavacamten vs. Beta-Blockers:

Mavacamten: Mavacamten acts directly on the molecular level to reduce excessive cardiac muscle contraction. It offers a targeted approach to manage HCM's underlying pathophysiology.

Beta-Blockers: Beta-blockers, such as metoprolol and atenolol, are commonly used to manage HCM symptoms. They reduce heart rate and blood pressure, alleviating some symptoms but not addressing the fundamental mechanical dysfunction.

2. Mavacamten vs. Calcium Channel Blockers:

Mavacamten: Mavacamten targets the mechanical abnormalities of HCM by inhibiting myosin, a key protein involved in muscle contraction. It offers a more precise mechanism of action.

Calcium Channel Blockers: Calcium channel blockers, like verapamil, can be used in HCM to reduce heart rate and improve diastolic function. However, they do not directly address the excessive muscle contraction.

3. Mavacamten vs. Surgical Myectomy:

Mavacamten: Mavacamten is a non-surgical option, which is particularly valuable for individuals who are not surgical candidates or those who prefer a non-invasive approach.

Surgical Myectomy: Surgical myectomy is a well-established surgical procedure to remove excess heart muscle and alleviate left ventricular outflow tract obstruction (LVOTO). It can provide more immediate relief but involves surgical risks and recovery time.

4. Mavacamten vs. Alcohol Septal Ablation (ASA):

Mavacamten: Mavacamten offers a non-invasive alternative to ASA, making it appealing for patients who want to avoid invasive procedures. It can be used in both obstructive and non-obstructive HCM.

Alcohol Septal Ablation: ASA is a catheter-based procedure that involves injecting alcohol into the septal artery to induce controlled tissue damage and reduce the obstruction. It is invasive and carries procedural risks.

5. Mavacamten vs. Gene Therapy (Emerging Treatment):

Mavacamten: Mavacamten is a pharmacological treatment that is currently available for HCM and has been tested in clinical trials.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

Gene Therapy: Gene therapy is an emerging field for HCM. It involves modifying or replacing the genetic mutations responsible for HCM. While promising, gene therapy is still in experimental stages and not widely available.

IV. CONCLUSION

In conclusion, Mavacamten, a myosin inhibitor, represents a groundbreaking and highly promising innovation in the field of cardiac therapeutics, particularly for hypertrophic cardiomyopathy (HCM). Key points to highlight in the conclusion about Mavacamten as a myosin inhibitor include:

- Precision Mechanism
- Clinical Efficacy
- Safety Profile
- Non-Invasive Approach

V. FUTURE PERSPECTIVES

Mavacamten, with its precise molecular targeting and demonstrated clinical benefits, holds great promise for individuals affected by HCM, marking a significant step forward in the quest to improve the lives of those living with this hereditary cardiac condition. As research and clinical experience with Mavacamten expand, it is likely to play an increasingly important role in the personalized and effective management of hypertrophic cardiomyopathy.

VI. AKNOWLEDGEMENT

I would like to express my sincere gratitude to M.s.Walunj.K.B for their invaluable guidance, support, and mentorship throughout this endeavor. Your unwavering commitment to excellence and your willingness to share your knowledge and expertise have been instrumental in the successful completion of this project.I would also like to extend my appreciation to my friend Chanchal Varhadi who have provided encouragement, insights, and a collaborative spirit. Your contributions have enriched the quality of this work.

REFERENCES

[1]. Bello J. Pellegrini M.V.(2023),Mavacamten , https://www.ncbi.nlm.nih.gov/books/NBK582152/

[2]. SR Ommen, C Semsarian, P Spirito, I Olivotto(2014), Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine,https://www.jacc.org/doi/abs/10.1016/j.jacc.2014.05.003

[3]. Susan J. Keam,(2022), Mavacamten: first approval https://link.springer.com/article/10.1007/s40265-022-01739-7

[4]. Michael A. Geeves(2016), Review: The ATPase mechanism of myosin and actomyosin,https://onlinelibrary.wiley.com/doi/abs/10.1002/bip.22853

[5]. SJ Rao, B Forst, AK Kanwal, A Kanwal, WS Aronow, SS Naidu(2023), Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential. https://www.tandfonline.com/doi/full/10.1080/13543784.2023.2166825

[6]. Mohammad Saber Tehrani, Mohammad Taghi Vardini, Parviz Abroomand Azar, Syed waqif Husain volume5(2010), Metaprolol : Activation of PPAR-γ prevents TERT-mediated pulmonary vascular remodeling in MCT-induced pulmonary hypertension https://www.sciencedirect.com/science/article/pii/S1452398123152692

[7]. C Chuang, S Collibee, L Ashcraft, W Wang(2021) , Discovery of Aficamten (CK-274) https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c01290

[8]. Olivotto, I., Oręziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., García-Pavía, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A. T., Kubánek, M., Wojakowski, W., Jensen, M. K., Gimeno-Blanes, J. R., Afshar, K., Myers, J., Hegde, S. M., Solomon, S. D., Sehnert, A. J., . . . Yamani, M. H. (2020). Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 396(10253), 759–769. https://doi.org/10.1016/s0140-6736(20)31792-x

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

[9]. Heitner, S. B., Jacoby, D., Lester, S. J., Owens, A. T., Wang, A., Zhang, D., Lambing, J. L., Lee, J., Semigran, M. J., & Sehnert, A. J. (2019). Mavacamten treatment for Obstructive Hypertrophic cardiomyopathy. Annals of Internal Medicine, 170(11), 741. https://doi.org/10.7326/m18-3016

[10]. Rohde, J. A., Roopnarine, O., Thomas, D. D., & Muretta, J. M. (2018). Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proceedings of the National Academy of Sciences of the United States of America, 115(32). https://doi.org/10.1073/pnas.1720342115

[11]. Mamidi, R., Li, J., Doh, C. Y., Verma, S., & Stelzer, J. E. (2018). Impact of the myosin modulator Mavacamten on force generation and Cross-Bridge behavior in a murine model of hypercontractility. Journal of the American Heart Association, 7(17). https://doi.org/10.1161/jaha.118.009627

[12]. Papadakis, M., Basu, J., & Sharma, S. (2020). Mavacamten: treatment aspirations in hypertrophic cardiomyopathy. The Lancet, 396(10253), 736–737. https://doi.org/10.1016/s0140-6736(20)31793-1

[13]. Capilupi, M. J., & Frishman, W. H. (2022, December 2). Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy. Cardiology in Review, 31(1), 45–51. https://doi.org/10.1097/crd.0000000000000433

[14]. Chin, A. C., & Day, S. M. (2022, July 11). Myosin modulators move forward with FDA approval of mavacamten. Nature Cardiovascular Research, 1(7), 595–596. https://doi.org/10.1038/s44161-022-00093-x

[15]. Gras, J. (2021). Mavacamten. Allosteric modulator of cardiac myosin, Treatment of hypertrophic cardiomyopathy, Treatment of heart failure with preserved ejection fraction. Drugs of the Future, 46(6), 443. https://doi.org/10.1358/dof.2021.46.6.3273821